Novartis stands behind Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy Read more
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial Read more
Sanofi : Dupixent (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis Read more
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute Read more
Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets Read more